Dual Inhibition of PI3K and mTORC1/C2 by PKI-587 (PF-05212384) as a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease and Its Effect on AKT-Signaling

被引：0
|
作者：
Freitag, H. [1 ]
Briest, F. [1 ]
Christen, F. [1 ]
Grass, I [1 ]
Lewens, F. [1 ]
Siegmund, B. [1 ]
Grabowski, P. [1 ]
机构：
[1] Charite, Berlin, Germany
来源：
NEUROENDOCRINOLOGY | 2015年 / 102卷 / 1-2期
关键词：
dual inhibition; pi3k; mtor; pki-587; rad001; signaling;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A5
引用
收藏
页码：80 / 80
页数：1
相关论文
共 4 条
  • [1] Phase I dose-escalation study of the dual PI3K/mTORC1/2 inhibitor Gedatolisib (PF-05212384) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumours
    Colombo, I.
    Genta, S.
    Martorana, F.
    Guidi, M.
    Samartzis, E. S. P.
    Brandt, S.
    Gaggetta, S.
    Moser, L.
    Pascale, M. R.
    Terrot, T.
    Sessa, C.
    Stathis, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S487 - S487
  • [2] Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
    Chapuis, Nicolas
    Tamburini, Jerome
    Green, Alexa S.
    Vignon, Christine
    Bardet, Valerie
    Neyret, Aymeric
    Pannetier, Melanie
    Willems, Lise
    Park, Sophie
    Macone, Alexandre
    Maira, Sauveur-Michel
    Ifrah, Norbert
    Dreyfus, Francois
    Herault, Olivier
    Lacombe, Catherine
    Mayeux, Patrick
    Bouscary, Didier
    CLINICAL CANCER RESEARCH, 2010, 16 (22) : 5424 - 5435
  • [3] Differential Suppressive Effects of Selective PI3K and mTOR and Dual PI3K/mTORC1/C2 Inhibition on Long-Term Cultured Primary Human Acute Lymphoblastic Leukemia (ALL) Cells Implicate a Distinct Role of mTORC2
    Badura, Susanne
    Tesanovic, Tamara
    Pfeifer, Heike
    Hohnloser, Catherine
    Liebermann, Marcus
    Serve, Hubert
    Ruthardt, Martin
    Ottmann, Oliver G.
    BLOOD, 2010, 116 (21) : 454 - 454
  • [4] Preclinical study of cytotoxicity and predictive markers of response to dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 with or without paclitaxel or nab-paclitaxel as a new therapeutic strategy in pancreatic cancer cell lines.
    Loaiza-Bonilla, Arturo
    Kittaneh, Muaiad
    Amado, Victor Daniel Guardiola
    Kovacs, Krisztina
    Merchan, Jaime R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
1